SSLCF (Simply Solventless Concentrates) Debt-to-EBITDA : 5.05 (As of Sep. 2025)

What is Simply Solventless Concentrates Debt-to-EBITDA?

Simply Solventless Concentrates SSLCF Debt-to-EBITDA is 5.05 as of Sep. 2025. The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, Simply Solventless Concentrates ranks better than 58.7% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Simply Solventless Concentrates's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $2.96 Mil. Simply Solventless Concentrates's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $8.11 Mil. Simply Solventless Concentrates's annualized EBITDA for the quarter that ended in Sep. 2025 was $2.19 Mil. Simply Solventless Concentrates's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2025 was 5.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Simply Solventless Concentrates's Debt-to-EBITDA or its related term are showing as below:

SSLCF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.4 Med: -1.24 Max: 1.2
Current: 1.16

During the past 4 years, the highest Debt-to-EBITDA Ratio of Simply Solventless Concentrates was 1.20. The lowest was -6.40. And the median was -1.24.

SSLCF's Debt-to-EBITDA is ranked better than
58.7% of 690 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs SSLCF: 1.16

Simply Solventless Concentrates (OTCPK:SSLCF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Simply Solventless Concentrates Debt-to-EBITDA Related Terms

Simply Solventless Concentrates Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Simply Solventless Concentrates's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simply Solventless Concentrates Debt-to-EBITDA Chart

Simply Solventless Concentrates Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-EBITDA

-0.03

-6.39

1.20

-2.45

Simply Solventless Concentrates Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25
Debt-to-EBITDA	Get a 7-Day Free Trial										-49.96	-2.10	0.53	0.92	5.05

SSLCF vs ZTS, UTHR: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Simply Solventless Concentrates's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Simply Solventless Concentrates Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simply Solventless Concentrates's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Simply Solventless Concentrates's Debt-to-EBITDA falls into.

Save Embed

Simply Solventless Concentrates Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Simply Solventless Concentrates's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(6.004	+	1.04)	/	-2.876
	=	-2.45

Simply Solventless Concentrates's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2025 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.96	+	8.113)	/	2.192
	=	5.05

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2025) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →

What does a Debt-to-EBITDA of 5.05 mean?

Simply Solventless Concentrates (SSLCF) has a Debt-to-EBITDA of 5.05 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Simply Solventless Concentrates. According to the industry distribution chart, Simply Solventless Concentrates ranks #285 out of 690 companies in the Drug Manufacturers industry, placing it in the top 41.3%.

Is Simply Solventless Concentrates' Debt-to-EBITDA too high?

Simply Solventless Concentrates' current Debt-to-EBITDA is 5.05. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Simply Solventless Concentrates' value of 5.05 is 202.4% above this industry median. Based on the distribution chart, Simply Solventless Concentrates ranks #285 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint.

How does Simply Solventless Concentrates' Debt-to-EBITDA compare to ZTS and UTHR?

According to the Drug Manufacturers industry distribution chart, Simply Solventless Concentrates ranks #285 out of 690 companies for Debt-to-EBITDA. This puts Simply Solventless Concentrates in the upper half of its industry. The industry median Debt-to-EBITDA is 1.67. Simply Solventless Concentrates' value of 5.05 is 202.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-EBITDA for a Drug Manufacturers company?

The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simply Solventless Concentrates's current Debt-to-EBITDA of 5.05 is 202.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-EBITDA mean?

A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Simply Solventless Concentrates. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simply Solventless Concentrates's current Debt-to-EBITDA is 5.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Simply Solventless Concentrates stock overvalued right now?

Simply Solventless Concentrates (SSLCF) has a current Debt-to-EBITDA of 5.05. The current Debt-to-EBITDA is 5.05 and 202.4% above the Drug Manufacturers industry median of 1.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-EBITDA calculated?

Debt-to-EBITDA is calculated from a company's financial statements. For Simply Solventless Concentrates (SSLCF), the current Debt-to-EBITDA is 5.05 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Simply Solventless Concentrates Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XCNQ:CLC XCNQ:HERB XCNQ:BBM TSXV:MUSH XCNQ:OILS TSXV:ELXR.H TSXV:DHB XCNQ:PLCN TSX:AVNT XCNQ:TGIF XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges HASH:Canada

Address 273209 Range Road, 20, Rocky View County, Calgary, AB, CAN, T0M 0E0

Website https://www.simplysolventless.ca

Simply Solventless Concentrates Ltd is a company that provides pure, potent, terpene-rich solvent less concentrates to discerning cannabis consumers. The company serves the recreational, medical, and business-to-business cannabis markets in Canada.